Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 8/20 | 0.51 |
| ▸ | BTK | Q06187 | 8/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22431592 | 0.94 | USP30 (0.52) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL4929565 | 0.85 | ALDH1A1 (0.56) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL15205596 | 0.85 | ALDH1A1 (0.60) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL22400981 | 0.85 | EGFR (0.73) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL30091792 | 0.85 | EGFR (0.73) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL22400976 | 0.84 | EGFR (0.75) | ALDH1A1EGFRBTK | |
| SCHEMBL30313815 | 0.84 | EGFR (0.75) | ALDH1A1EGFRBTK | |
| SCHEMBL22405035 | 0.82 | BTK (0.73) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL21525140 | 0.82 | ALDH1A1 (0.59) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL15205971 | 0.81 | ALDH1A1 (0.58) | ALDH1A1NPC1MAPTMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | BTK, SYK, LCK | ALDH1A1 4793/4885NPC1 3356/4885MAPT 2566/4885 |
| US-11542249-B2 | BTK inhibitor compounds | BTK, SYK, LCK | ALDH1A1 4731/4885NPC1 3309/4885MAPT 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.